Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics
CHRS Price/Volume Stats
| Current price | $2.17 | 52-week high | $8.65 |
| Prev. close | $2.20 | 52-week low | $1.43 |
| Day low | $2.12 | Volume | 854,471 |
| Day high | $2.20 | Avg. volume | 3,927,384 |
| 50-day MA | $2.40 | Dividend yield | N/A |
| 200-day MA | $3.21 | Market Cap | 244.59M |
CHRS Stock Price Chart Interactive Chart >
Coherus BioSciences, Inc. (CHRS) Company Bio
Coherus Biosciences is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. The company was founded in 2010 and is based in Redwood City, California.
Latest CHRS News From Around the Web
Below are the latest news stories about COHERUS BIOSCIENCES INC that investors may wish to consider to help them evaluate CHRS as an investment opportunity.
Why Coherus BioSciences Stock Jumped TodayCoherus finally received FDA approval for its Udenyca OnBody injector system. |
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca OnbodyThe FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news. |
These Stocks Moved the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and MoreA report says Tesla plans a revamped version of the Model Y from its Shanghai plant, while Apple shares are on pace to fall for a fifth-straight session. |
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving pegfilgrastim – REDWOOD CITY, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer, today announced that the U.S. Food |
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall StreetThese two biotech stocks could be poised for a trend reversal. |
CHRS Price Returns
| 1-mo | -2.25% |
| 3-mo | -11.79% |
| 6-mo | -38.87% |
| 1-year | -73.63% |
| 3-year | -84.92% |
| 5-year | -85.25% |
| YTD | -34.83% |
| 2023 | -57.95% |
| 2022 | -50.38% |
| 2021 | -8.17% |
| 2020 | -3.47% |
| 2019 | 98.95% |
Continue Researching CHRS
Want to do more research on Coherus BioSciences Inc's stock and its price? Try the links below:Coherus BioSciences Inc (CHRS) Stock Price | Nasdaq
Coherus BioSciences Inc (CHRS) Stock Quote, History and News - Yahoo Finance
Coherus BioSciences Inc (CHRS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...